(Solid Tumors) Is Enhertu Effective?
(Solid Tumors) Is Enhertu Effective?
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
(Solid Tumors) Is Enhertu Effective?
- June 28, 2023
- Read time: 1 minute
From June 2-6, 2023, Funda Meric-Bernstam and colleagues from Memorial Sloan Kettering Cancer Center presented efficacy and safety results of Enhertu treatment in HER2-positive, advanced solid tumor patients from the DPT02 Phase 2 clinical trial at ASCO 2023 in Chicago, USA.
The DPT02 Phase 2 clinical trial was an open-label trial conducted jointly at multiple facilities in the United States and Japan. HER2-positive, advanced solid tumor patients received Enhertu 5.4-6.4 mg/kg (every three weeks) until disease progression or adverse events occurred. The primary endpoint was objective response rate, with secondary endpoints including duration of response, disease control rate, progression-free survival, overall survival, and safety.
Results from 267 patients at a median follow-up of 9.7 months showed: primary endpoint objective response rate of 37.1%, secondary endpoint median duration of response of 11.8 months; in HER2-positive patients, objective response rate was 61.3% with median duration of response of 22.1 months.
Regarding safety, Grade 3+ adverse events occurred in 58.4% of patients, treatment discontinuation due to adverse events in 11.6%, and interstitial lung disease/pneumonitis in 6.7%.
Based on Phase 2 clinical trial results, Funda Meric-Bernstam and colleagues concluded: HER2-positive, advanced solid tumor patients treated with Enhertu demonstrated good response rates with controllable adverse effects. Enhertu has the potential to become a new treatment option for HER2-positive solid tumor patients.
Source: https://meetings.asco.org/abstracts-presentations/220035
Key to High-Aggressiveness Pancreatic Cancer Discovered! New Immune Enhancer Assists Cancer Immunotherapy Kyoto University Launches iPS Cell Cancer Treatment!
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4